Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSD | P07339 | 14/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | REN | P00797 | 1/20 | 0.40 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29550853 | 0.91 | BACE1 (0.47) | CTSDBACE1RXFP1 | |
| SCHEMBL30739470 | 0.91 | BACE1 (0.45) | CTSDBACE1RXFP1REN | |
| SCHEMBL30739462 | 0.86 | CTSD (0.44) | CTSDBACE1RXFP1REN | |
| SCHEMBL30867027 | 0.85 | BACE1 (0.44) | BACE1RXFP1 | |
| SCHEMBL29445234 | 0.84 | BACE1 (0.40) | CTSDBACE1 | |
| SCHEMBL30733157 | 0.83 | F2RL1 (0.41) | CTSDF2RL1 | |
| SCHEMBL29445196 | 0.82 | BACE1 (0.46) | CTSDBACE1 | |
| SCHEMBL30665612 | 0.81 | BACE1 (0.47) | CTSDBACE1 | |
| SCHEMBL31257047 | 0.81 | MME (0.43) | CTSD | |
| SCHEMBL14342413 | 0.81 | BACE1 (0.46) | CTSDBACE1RXFP1F2RL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240252507-A1 | SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF | SOLENO THERAPEUTICS, INC. | 2024-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240252507-A1 | SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF | KCNJ1, KCNJ11, KCNJ2 | CTSD 3605/4885BACE1 1991/4885RXFP1 2206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.